drug · protein
bulevirtide
pre_registrationupdated 6mo agoby $GILD GILEAD SCIENCES, INC.🔗 ChEMBL
community read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for hepatitis d virus infection and viral disease and 3 investigational indications.
targets
Hepatic sodium/bile acid cotransporter
all catalysts(0)
nothing on the calendar yet
Trials studying bulevirtide
- phase3Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
- —Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
- —Expanded Access for Bulevirtide
- phase3A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
- phase3A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
- phase1Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
- phase2A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
- phase1A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
News(2)
- Vir's hepatitis delta combo tamps down virus as Gilead showdown loomsVir Biotechnology is targeting a mid-2027 regulatory submission for its monthly chronic hepatitis delta regimen, with head-to-head data against Gilead’s Hepcludex expected next quarter.biospace · 7d ago
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) InfectionToday, the U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis (advanced liver scarr…fda_press · 5mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that